Shares of Immatics (NASDAQ:IMTXW – Get Free Report) dropped 14.1% during mid-day trading on Monday . The stock traded as low as $0.77 and last traded at $0.85. Approximately 5,304 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 7,647 shares. The stock had previously closed at $0.99.
Immatics Stock Down 14.1 %
The firm’s fifty day moving average is $1.85 and its 200-day moving average is $2.48.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
- Five stocks we like better than Immatics
- 3 Fintech Stocks With Good 2021 Prospects
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- What is the Dow Jones Industrial Average (DJIA)?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
